Latest Medical Technology News
Clever Culture Posts 3 Fully Invoiced APAS Sales in Q1 FY27
TALi Digital Appoints William Hamilton as CEO and Managing Director
Resonance Health’s Preliminary Liver Fibrosis Data Aligns With FibroScan Benchmark
PainChek Locks in 1,800 New UK Licences With Hallmark Across 23 Care Homes
OncoSil Study Shows Tumours Held in Check for All 16 Pancreatic Cancer Patients
ImpediMed Hires Cancer Survivorship Leader to Expand SOZO Across Care Settings
Adherium Partners With FLASS to Expand Hailie Into Central Florida
Medical Devices ETF Chart
Medical Technology Analysis
ResMed Stock: What a US$253 Price Assumes Before Earnings
Why Allogeneic CAR-T Is a Logistics Fix, Not a Science Bet
How Clinic Control, Not Technology, Built the Hearing Aid Oligopoly
What Telix’s Pixclara Approval Actually Means for the Stock
Pro Medicus FY26: What the Result Settles and What It Doesn’t
Why ResMed Fell 7% on a Quarter That Didn’t Disappoint
Why BTK Inhibitor Resistance Opens a Door for Off-the-Shelf CAR-T
How a Medtech Stock Beat Every Miner on the ASX 200 in FY2026
Why Imugene’s Fast Track Win in Marginal Zone Lymphoma Matters
Medical Technology Guides & Education
What the 5-Gate Pharma Adoption Process Tells Investors
8 Questions to Test a Diagnostics Merger on Structure, Not Spin
Why a US$740M AI Hearing Raise Reprices ASX Tech Stocks
How ASX Medtech Stocks Win in the World’s Most Cautious Market
What an 86% Untreated Market Means for ASX Health Stocks
How to Read Clinical Milestones in ASX Biotech Stocks
Why T-Cell Exhaustion Defines the CAR-T Bet for ASX Biotech Investors
How to Value ASX Medtech Stocks: a 5-Step Framework
ATEC Is Not the Pure Tech ETF Most Investors Think It Is
Discover More in the Medical Devices Hub
Go to Hub
Resonance Health Launches $6M Placement to Back Liver Scan and Clinical Trial Growth
Resonance Health’s Preliminary Liver Fibrosis Data Aligns With FibroScan Benchmark
ResMed Stock: What a US$253 Price Assumes Before Earnings
OncoSil Study Shows Tumours Held in Check for All 16 Pancreatic Cancer Patients
ImpediMed Hires Cancer Survivorship Leader to Expand SOZO Across Care Settings
Adherium Partners With FLASS to Expand Hailie Into Central Florida
Fisher & Paykel Healthcare Contains Cyber Breach With No Hit to Supply or Earnings
OncoSil Registry Data Presented at EANM Shows 10 Pancreatic Patients Resected
Anteris Wins German Green Light to Start Recruiting for Its Pivotal Heart Valve Trial
Featured ASX Medical Technology Announcements
4DMEDICAL Ltd Wins TGA Approval for Lung Imaging Tool in Australia
Video
4DMedical Eyes $2.5B PE Market as CLEAR Program Targets 5M Annual US Scans
Video
4DMedical Eyes $2.5B Pulmonary Market With Contrast-Free Imaging Tech
Video
4DMedical Acquires contextflow for European Expansion at 6.5% of Cash Balance
Video
4DMedical Secures Commercial SimonMed Contract Across 170 US Imaging Centres
Video
PainChek Locks in 4,000 UK Licences as Care Homes Prioritise Pain Tech
Video
4DMedical Study Shows Its CT:VQ Tech Nearly Doubles Lung Surgery Success Rates
Video
Enlitic Lands First New Zealand Customer as It Goes Live at 65-Clinic Network
Nova Eye Lifts FY26 Sales Guidance to US$22-23M After Record USA Sales in April
Video
Latest ASX Medical Technology Videos
Medical Technology Stocks: Innovation Trends, Earnings and Investment Analysis
Medical technology spans implantable devices, robotic surgery systems, digital health platforms, remote patient monitoring, and AI-driven clinical tools, creating a sector with diverse risk profiles and return drivers. The most attractive medtech businesses combine proprietary technology with high switching costs, recurring consumable revenue, and international scalability. ASX-listed medical technology companies have demonstrated that global market success is achievable from an Australian base, with several companies generating the majority of their revenue internationally. Regulatory approval from the FDA and CE mark in Europe remains the key commercial gateway, and approval timelines are closely tracked by investors. StockWire X monitors medical technology company results, product launches, clinical study data, and M&A activity across the sector.
Frequently Asked Questions
What is a medical technology salary and is it relevant to investors?
Medical technology salary data is relevant to investors as an indicator of the talent market and R&D cost dynamics for medtech companies. Rising engineering and clinical specialist salaries can pressure margins for capital-light medtech businesses. More importantly for investors, salary benchmarks indicate how aggressively medtech companies are investing in innovation talent relative to their revenue base.
What are the best medical technology stocks to invest in?
The best medical technology investment candidates combine proprietary technology with regulatory approvals, a large and growing addressable market, recurring revenue from consumables or software, and management with a track record of commercial execution. ASX-listed medtech companies with US market penetration typically command higher valuations given the scale of the US healthcare system. StockWire X covers medical technology stocks comprehensively.
What is the outlook for the medical technology sector in 2025?
The medical technology sector outlook remains positive, driven by ageing demographics, ongoing procedure volume recovery post-COVID, AI integration in clinical tools, and continued innovation in minimally invasive surgery, remote monitoring, and precision diagnostics. Near-term headwinds include hospital capex budget pressures and supply chain normalisation. StockWire X tracks the sector developments influencing medical technology stock performance.
What is the medical technology sector and how does it differ from pharmaceuticals?
The medical technology sector encompasses companies developing and manufacturing medical devices, diagnostic equipment, surgical instruments, and healthcare IT systems. Unlike pharmaceutical companies, medtech companies often sell capital equipment supplemented by recurring consumable and service revenue. The development pathway for medical devices typically involves clinical evidence generation and regulatory clearance rather than multi-phase drug trials, resulting in shorter and less capital-intensive development programmes.
How do hospital purchasing decisions affect medical technology company revenue patterns?
Hospital purchasing committees create specific sales cycle characteristics for medical technology companies. Large capital equipment purchases go through extended evaluation and approval processes, creating longer sales cycles and lumpy revenue recognition. However, once a medical technology product is adopted into clinical workflow, switching costs are high because of staff training requirements and workflow integration. This creates durable recurring revenue streams from consumables and service contracts.
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time